$ News

Form 8.3 -Avadel Pharmaceuticals plc

Form 8.3

Rechecking Avadel Pharmaceuticals (AVDL) Valuation After Strong Share Price Momentum

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

Avadel Pharmaceuticals Shareholders Approve Proposed Takeover By Alkermes

Do Options Traders Know Something About Avadel Pharmaceuticals Stock We Don't?

Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data

Assessing Avadel Pharmaceuticals (AVDL) Valuation After Strong 1-Year Share Price Performance

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia

Avadel Pharmaceuticals Completes Enrollment In Phase 3 REVITALYZ Trial Of Once-At-Bedtime LUMRYZ For Idiopathic Hypersomnia, Data Expected In Q2 2026

Form 8.3 - Amendment

Has Avadel’s 115% Rally in 2024 Already Priced In Its Narcolepsy Breakthrough?

Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge

Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $22.5

AVDL stock has given up its prior gain. Avadel Pharmaceuticals shares were trading higher after Alkermes increased the buyout offer to up to $22.50 per share.

Avadel Pharmaceuticals shares are trading higher after Alkermes increased the buyout offer to up to $22.50 per share.

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $20

Avadel Pharmaceuticals Q3 EPS $0.00 Misses $0.07 Estimate, Sales $77.467M Beat $73.574M Estimate

Form 8.3